Search Results for “research” – Page 287 – media

More than 2,000 immune-oncology drugs now in development

A new report has found that there are more than 2,000 immunotherapy drugs now in development for cancer, with 940 of these in clinical stage development and 1,064 at the preclinical stage.
- Source: pharmatimes
- 477
- December 11, 2017
immuno-oncology immunotherapy drugs immuotherapy agents
electroCore completes $70 million series B funding round

electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, has announced it completed its Series B financing that has brought in just over $70 million of capital to the company.
- Source: globalbiotechinsights
- 525
- December 8, 2017
headache Market Views neuromodulation Series
Tudorza reduces exacerbations and demonstrates cardiovascular safety in COPD patients

AstraZeneca today announced positive top-line results of the Phase IV ASCENT trial for Tudorza Pressair (aclidinium bromide 400 μg, twice-daily), a long-acting muscarinic antagonist (LAMA), in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), with a history of cardiovascular disease and/or significant cardiovascular risk factors.
- Source: Astrazeneca
- 627
- December 8, 2017
AstraZeneca cardiovascular Clinical Trials COPD
FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Avastin® (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease). Avastin was previously granted provisional approval in this setting under the FDA's accelerated approval program.
- Source: Gene
- 559
- December 8, 2017
FDA Genentech New Approvals Roche
Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, announced the completion of a $49.5 million Series A financing to further build its technology platform and advance its lead programs toward clinical development.
- Source: Businesswire
- 557
- December 8, 2017
CAR–T Market Views Series
Personalised epilepsy seizure prediction a possibility with AI

The idea of personalised seizure prediction for epilepsy is closer to becoming a reality thanks to new research published today by the University of Melbourne and IBM Research-Australia.
- Source: medicalxpress
- 655
- December 7, 2017
AI epilepsy Researches
First Video Game Therapy Heads to FDA As Akili Touts ADHD Study Win

For the first time ever, a mobile video game used to assess and treat a disease is headed for an FDA review.
- Source: xconomy
- 490
- December 7, 2017
ADHD Attention Performance Index Company Insight video game
Cambridge’s Exonics Therapeutics Scores $40M

Exonics Therapeutics closed on a $40 million Series A financing. It was led by The Column Group.
- Source: biospace
- 534
- December 7, 2017
DMD Market Views neuromuscular Series
Weight Loss Really Can Reverse Diabetes, New Study Finds

in a paper published in the Lancet, researchers in the UK describe a landmark study in which people with diabetes went into remission—just by losing weight.
- Source: in a paper published in the Lancet, researchers in the UK describe a landmark study in which people with diabetes went into remission—just by losing weight.
- 544
- December 7, 2017
diabetes weight loss
Gallup Pakistan report

In a report by Gallup Pakistan short roundup of health infrastructure in Pakistan 2000-2015 based on Pakistan Economic Survey 2015-2016, it is mentioned that “Pakistan was unable to meet its Millennium Development Goals (MDGs) on health and ranks 149 in 188 countries in the first global assessment of countries.
- Source: pakistantoday
- 505
- December 6, 2017
health infrastructure hepatitis Market Views papillomavirus

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.